Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Heron Therapeutics (HRTX) and Omeros (OMER) Top Cantor Fitzgerald's Most Shorted List; Amgen (AMGN) and PDS (PDSB) Seeing Biggest Increases
-
Heron Therapeutics (HRTX) PT Lowered to $20 at Cantor Fitzgerald
-
Heron Therapeutics (HRTX) and Omeros (OMER) Top Cantor Fitzgerald's Most Shorted List
-
VYNE Therapeutics (VYNE) and Ardelyx (ARDX) Top Cantor Fitzgerald's Most Shorted Biotech List
-
Companies with NDRs 7/29
-
Heron Therapeutics (HRTX) Approval 'Positive, Even Without The Cherry on Top' - Cantor Fitzgerald
-
Heron Therapeutics (HRTX) PT Lowered to $26 at Cantor Fitzgerald, After Receiving Complete Response Letter for HTX-011
-
Cantor Fitzgerald Reiterates Overweight Rating on Heron Therapeutics (HRTX)
-
Heron Therapeutics (HRTX) HRX-011 Resubmission a 'Significant Positive' - Cantor Fitzgerald
-
Heron Therapeutics (HRTX) PT Lowered to $41 at Cantor Fitzgerald
-
Cantor Fitzgerald Remains Bullish on Heron Therapeutics (HRTX) Following NDA Acceptance
-
Heron Therapeutics (HRTX) Defended at Cantor
-
Heron Therapeutics (HRTX) PT Raised to $50 at Cantor Fitzgerald
-
Two More Positive HTX-011 Studies Supports Bullish Heron Therapeutics (HRTX) Thesis - Cantor Fitzgerald
-
Heron Therapeutics (HRTX) PT Raised to $40 at Cantor Fitzgerald
-
Heron Therapeutics (HRTX) Prices $150M Common Stock Offering
-
Heron Therapeutics Announces Pricing of Public Offering of Common Stock
-
Heron Therapeutics (HRTX) Plans Public Offering of Common Stock
-
Heron Therapeutics Announces Public Offering of Common Stock
-
Heron Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Cantor Fitzgerald Assumes Heron Therapeutics (HRTX) at Overweight
-
Heron Therapeutics (HRTX) PT Raised to $31 at Cantor Fitzgerald
-
Heron Therapeutics (HRTX) PT Lowered to $30 at Cantor Fitzgerald Following $167.3M Capital Raise
-
Heron Therapeutics (HRTX) Prices Offering at $12.20/Share
-
Heron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
-
Heron Therapeutics (HRTX): Sustinol Trumps Positive HTX-011 Data - Cantor
-
Cantor Fitzgerald Starts Heron Therapeutics (HRTX) at Buy

